2007
DOI: 10.1016/j.vaccine.2007.03.040
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
25
0
2

Year Published

2008
2008
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 44 publications
(27 citation statements)
references
References 35 publications
0
25
0
2
Order By: Relevance
“…With the expression of the capsid protein (rORF2p) in the baculovirus expression system [17] , a preliminary study was conducted during [2003][2004][2005][2006]. Since all the FHF patients were admitted to a single unit of a medical college hospital, the treatment protocol was not responsible for differential outcome of FHF.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…With the expression of the capsid protein (rORF2p) in the baculovirus expression system [17] , a preliminary study was conducted during [2003][2004][2005][2006]. Since all the FHF patients were admitted to a single unit of a medical college hospital, the treatment protocol was not responsible for differential outcome of FHF.…”
Section: Discussionmentioning
confidence: 99%
“…10 6 cells/well were set up in 6-well plate (Nunc, Denmark). Cells were stimulated with HPLC purified rORF2p from genotype-1 HEV [17] . Supernatants from cultured cells were harvested after 72 h and stored at -70 °.…”
Section: Stimulation Of Pbmcs and Cytokine Assaymentioning
confidence: 99%
“…HEV regularly causes epidemics in many tropical and subtropical countries. In India, 101 outbreaks were confirmed by serological analysis in the state of Maharashtra in the last 5 years (6), and the lifetime risk of HEV infection exceeds 60% (28). Sporadic cases have also been reported in regions where HEV is endemic, as well as in areas where it is not endemic.…”
mentioning
confidence: 99%
“…The vaccine was also found to be immunogenic and resulted in vaccinated persons in a high level of protection against infection with HEV-1 prevalent in Nepal [213]. Additional experimental vaccines based on recombinant HEV proteins or HEV DNA coding for ORF2 are being investigated in various model systems for their immunogenicity and cross-reactivity [24,214,215,216]. Up to now no licenced vaccines are available in Europe.…”
Section: Recipientsmentioning
confidence: 99%